|Articles|October 8, 2014

NSCLC (Issue 4)
Volume 4
Issue 1

The Importance of Biomarkers for Lung Cancer

Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.

Articles in this issue

almost 12 years ago

Article

The Implementation of Personalized Medicine for Lung Cancer Patients

almost 12 years ago

Article

The Benefit of Treating Lung Cancer with Immunotherapy

almost 12 years ago

Article

The Cancer Genome Atlas Plays Role in Future Therapies for NSCLC

almost 12 years ago

Article

In Practice: Systemic Treatment for Metastatic NSCLC

almost 12 years ago

Article

Clinical Trial Profile: The OAK Study

almost 12 years ago

Article

Managing Side Effects of Targeted Therapies for NSCLC May Improve Outcomes

almost 12 years ago

Article

Optimizing of Therapeutic Sequencing Being Studied in NSCLC

Stay up to date on practice-changing data in community practice.

The Importance of Biomarkers for Lung Cancer

Articles in this issue

Related Content

Reactive, Lineage-by-Lineage Care Still Defines Anemia and Thrombocytopenia Management in ES-SCLC

VISUALIZE Trial: Abenacianine Helps Surgeons Locate Hard-to-Find Lung Tumors

Adjuvant Alectinib Maintains Manageable Safety, QoL in NSCLC

Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC

Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Washington State Medical Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Nevada Oncology Society

Louisiana Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

AUA/SUO Issue 2026 Update to Non–Muscle-Invasive Bladder Cancer Guideline

Tarlatamab Plus Durvalumab Improves Survival in First-Line ES-SCLC

Dr Pant Discusses Next Steps in Daraxonrasib Development for Pancreatic Cancer

FDA Approves Camizestrant Plus CDK4/6 Inhibitor for ESR1-Mutant Breast Cancer

Expanding Blood Cancer Care With the Next Frontier of T-Cell Immunotherapy